Back to Results

A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00445978

Condition

Sickle Cell Disease

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This Phase 2a, multicenter, open-label, dose-escalation study is designed to assess the safety and biologic activity of daily oral administration of 4 escalating doses of sapropterin dihydrochloride over 16 weeks in subjects with sickle cell disease. During an optional extension phase, the study will assess the safety, tolerability, and efficacy of extended treatment with sapropterin dihydrochloride, for a total of up to 2 years; The extension phase of this study was terminated.

Eligibility Criteria

Birth Sex

All

Age

From 15 Years

Healthy Volunteers

No

Drug/Treatment:

Sapropterin Dihydrochloride

Phase:

Phase 2

Study Type:

Interventional

Number of Participants:

32

Study Started:

2007-05

Study Updated:

2021-02-25

Trial Locations

  • Washington, District of Columbia, United States

  • Augusta, Georgia, United States

  • Savannah, Georgia, United States

  • Indianapolis, Indiana, United States

  • Detroit, Michigan, United States

  • Flint, Michigan, United States

  • Hackensack, New Jersey, United States

  • Chapel Hill, North Carolina, United States

  • Philadelphia, Pennsylvania, United States

  • Galveston, Texas, United States

  • Norfolk, Virginia, United States

  • Richmond, Virginia, United States

Inclusion Criteria

  • Diagnosis of SCD, as confirmed by hemoglobin electrophoresis.
  • At least 15 years of age.
  • Dosage of medication(s) used to treat cardiac disease, hypertension (eg, calcium-channel blockers), elevated cholesterol, iron overload (eg, desferoxamine) and type 2 diabetes must be unchanged for at least 30 days prior to Screening.
  • Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.
  • Willing and able to comply with all study procedures.
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
  • Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been menopausal for at least 2 years, or had a tubal ligation at least 1 year prior to Screening, or who have had a total hysterectomy.

Exclusion Criteria

  • Requires chronic hypertransfusion therapy.
  • Sickle cell crisis during the 30 days prior to Screening.
  • Myocardial infarction, cerebral vascular accident, or pulmonary embolism during the 6 months prior to Screening.
  • History of bone marrow or hematopoietic stem cell transplantation.
  • Hepatic dysfunction (alanine aminotransferase [ALT][SGPT] > 2 times the upper limit of normal [ULN]).
  • Renal dysfunction with serum creatinine > 1.5 mg/dL.
  • On outpatient oxygen therapy, or continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) therapy.
  • Uncontrolled hypertension (defined as blood pressure > 135/85 mm Hg) at Screening.
  • History of chronic symptomatic hypotension.
  • Concurrent disease or condition that would interfere with study participation or safety, including, but not limited to: bleeding disorders, history of syncope or vertigo, severe gastroesophageal reflux disease (GERD), arrhythmia, organ transplant, organ failure, type 1 diabetes mellitus (subjects with type 2 diabetes are allowed), or serious neurological disorders (including seizures).
  • Hydroxyurea therapy during the 3 months prior to Screening or anticipated need for hydroxyurea during the course of the study.
  • Treatment with any phosphodiesterase (PDE) 5 inhibitor (Viagra®, Cialis®, Levitra® or Revatio™), any PDE 3 inhibitor (eg, cilostazol, milrinone, or vesnarinone), pentoxifylline (Trental®), nitrate/nitrite-based vasodilators, bosentan (Tracleer®), L-arginine, levodopa, or dietary supplements containing L-arginine or gingko biloba within 30 days prior to Screening, or anticipated need for treatment with any of these agents during the course of the study.
  • Requirement for concomitant treatment with any drug known to inhibit folate metabolism (eg, methotrexate).
  • Previous treatment with vascular endothelial growth factor (VEGF) or VEGF inhibitors.
  • Has known hypersensitivity to sapropterin dihydrochloride or its excipients.
  • Use of any investigational product, device, or any formulation of BH4 within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
  • Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us